Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spring Awakening: NDA Submissions To Watch For

Executive Summary

If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March. 

Related Content

More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
Phase III Data Support Catalyst's NDA Resubmission For Firdapse
Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III
Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Will Palatin's Phase III Female Sex Endpoint Swap Pass With FDA?

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts